Evaluating the efficacy of doripenem against Staphylococcus aureus in vancomycin-resistant strains.

Determination of antibiotic susceptibility is a crucial aspect of antimicrobial therapy. The objective of this study was to determine the specific susceptibility of Staphylococcus aureus (SA) to the antibiotic doripenem. A total of 180 clinical isolates from VRSA patients were tested against doripenem using minimum inhibitory concentration (MIC) and disk diffusion tests. The overall findings indicated that doripenem exhibited a high sensitivity level for SA isolates, with an MIC50 of 60 μg/mL and a MIC90 of 0.5 mg/mL. Additionally, the antimicrobial activity of doripenem, both alone and in combination with amoxiclav against VRSA showed consistent biofilm inhibition within 48 and 24 h, respectively. Furthermore, these results demonstrate that doripenem maintains its high efficacy against VRSA and the combination of amoxiclav with doripenem presents a potential option for managing these resistant infections.